Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Searching for pharmacogenomic markers: The synergy between omic and hypothesis-driven research
Autore:
Weinstein, JN;
Indirizzi:
NCI, Mol Pharmacol Lab, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892NCI, Mol Pharmacol Lab, Bethesda, MD 20892 USA
Titolo Testata:
DISEASE MARKERS
fascicolo: 2, volume: 17, anno: 2001,
pagine: 77 - 88
SICI:
0278-0240(2001)17:2<77:SFPMTS>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
NATIONAL-CANCER-INSTITUTE; TUMOR-CELL-LINES; DIFFERENTIAL CYTOTOXICITY DATA; ANTICANCER DRUG SCREEN; MOLECULAR PHARMACOLOGY; CLUSTER-ANALYSIS; EXPRESSION PATTERNS; ELLIPTICINE ANALOGS; DISCOVERY; INFORMATION;
Keywords:
microarray; genomics; proteomics; omics; cancer; cell line; pharmacology; pharmacogenomics; molecular marker; cancer therapy; clustered image map; MedMiner;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Weinstein, JN NIH, Bldg 37,Rm 4E-28,9000 Rockville Pike, Bethesda, MD 20892 USA NIH Bldg 37,Rm 4E-28,9000 Rockville Pike Bethesda MD USA 20892
Citazione:
J.N. Weinstein, "Searching for pharmacogenomic markers: The synergy between omic and hypothesis-driven research", DIS MARKER, 17(2), 2001, pp. 77-88

Abstract

With 35,000 genes and hundreds of thousands of protein states to identify,correlate, and understand, it no longer suffices to rely on studies of onegene, gene product, or process at a time. We have entered the "omic" era in biology. But large-scale omic studies of cellular molecules in aggregate rarely can answer interesting questions without the assistance of information from traditional hypothesis-driven research. The two types of science are synergistic. A case in point is the set of pharmacogenomic studies that we and our collaborators have done with the 60 human cancer cell lines of the National Cancer Institute's drug discovery program. Those cells (the NCI-60) have been characterized pharmacologically with respect to their sensitivity to > 70, 000 chemical compounds. We are further characterizing them atthe DNA, RNA, protein, and functional levels. Our major aim is to identifypharmacogenomic markers that can aid in drug discovery and design, as wellas in individualization of cancer therapy. The bioinformatic and chemoinformatic challenges of this study have demanded novel methods for analysis and visualization of high-dimensional data. Included are the color-coded "clustered image map" and also the MedMiner program package, which captures andorganizes the biomedical literature on gene-gene and gene-drug relationships. Microarray transcript expression studies of the 60 cell lines reveal, for example, a gene-drug correlation with potential clinical implications - that between the asparagine synthetase gene and the enzyme-drug L-asparaginase in ovarian cancer cells.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 11:51:15